NCT01841736 2026-03-18
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00454363 2020-04-03
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00625846 2020-02-26
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01247571 2019-08-08
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00861913 2018-10-16
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00509587 2018-08-08
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01340794 2017-09-21
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00459381 2017-03-15
Pazopanib in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00454571 2016-02-10
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00454142 2015-12-17
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00471536 2014-05-30
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed